# AQUINNAH PHARMACEUTICALS, INC.: Development of a novel oral brain penetrant therapeutic for ALS disease

**Lab Budget Score:** 70/100

| Field | Value |
|---|---|
| Organization | AQUINNAH PHARMACEUTICALS, INC. |
| Location | NEWTON, MA |
| Project | Development of a novel oral brain penetrant therapeutic for ALS disease |
| Project number | 5R44NS141531-02 |
| Mechanism | R44 |
| Institute | National Institute of Neurological Disorders and Stroke |
| Award | $1,499,529 |
| Awarded | 2026-09-02 |
| Project period | 2025-06-15 to 2027-05-31 |
| UEI | T6T9BUCQMDB1 |

## Why this score
- Award of $1M or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11354018). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.